BlackRock Inc. lifted its stake in shares of Kura Oncology (NASDAQ:KURA) by 49.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,524,817 shares of the company’s stock after purchasing an additional 502,296 shares during the quarter. BlackRock Inc. owned about 5.05% of Kura Oncology worth $23,331,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in shares of Kura Oncology during the 3rd quarter worth $802,000. Alps Advisors Inc. acquired a new position in shares of Kura Oncology during the 4th quarter worth $512,000. California State Teachers Retirement System grew its stake in shares of Kura Oncology by 24.5% during the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after purchasing an additional 6,200 shares during the period. Bailard Inc. acquired a new position in shares of Kura Oncology during the 4th quarter worth $517,000. Finally, Nationwide Fund Advisors grew its stake in shares of Kura Oncology by 66.9% during the 3rd quarter. Nationwide Fund Advisors now owns 42,981 shares of the company’s stock worth $643,000 after purchasing an additional 17,223 shares during the period. 58.56% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on KURA. ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. BidaskClub cut shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 16th. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Wednesday, March 21st. Cann reaffirmed a “buy” rating and set a $27.00 price target on shares of Kura Oncology in a research note on Thursday, April 5th. Finally, Wedbush began coverage on shares of Kura Oncology in a research note on Wednesday, December 20th. They set an “outperform” rating and a $19.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $22.00.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). equities research analysts expect that Kura Oncology will post -1.43 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/04/16/kura-oncology-kura-stake-boosted-by-blackrock-inc.html.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.